CompletedPhase 1NCT01073306

Safety and Immune Response to an Investigational Dengue Type 2 Vaccine

Studying Dengue fever

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator
Kawsar Talaat, MD, MD
Johns Hopkins Bloomberg School of Public Health
Intervention
Investigational Vaccine for Dengue Virus Subtype 2(biological)
Enrollment
18 enrolled
Eligibility
18-50 years · All sexes
Timeline
20102010

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01073306 on ClinicalTrials.gov

Other trials for Dengue fever

Additional recruiting or active studies for the same condition.

See all trials for Dengue fever

← Back to all trials